Fineline Cube

Follow:
14409 Articles
CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%
Policy / Regulatory

CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%

Hengrui's Three Oncology Assets Win NMPA Clinical Trial Approval
CompanyDrug

Hengrui’s Three Oncology Assets Win NMPA Clinical Trial Approval

Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential
CompanyDrug

Humanwell’s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential

Innovent's mazdutide 9mg Obesity Application Accepted by NMPA
CompanyDrug

Innovent’s mazdutide 9mg Obesity Application Accepted by NMPA

Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH
CompanyDrug

Fosun’s Luvometinib Gets NMPA Priority Review for Pediatric LCH

Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma
CompanyDeals

Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma

Otsuka's VOYXACT Wins FDA Accelerated Approval for IgAN, First APRIL Blocker
CompanyDrug

Otsuka’s VOYXACT Wins FDA Accelerated Approval for IgAN, First APRIL Blocker

Wuzhong Pharma Faces Mandatory Delisting After CSRC Violations
Company

Wuzhong Pharma Faces Mandatory Delisting After CSRC Violations

Novartis's Itvisma Wins FDA Approval as First Gene Therapy for SMA
CompanyDrug

Novartis’s Itvisma Wins FDA Approval as First Gene Therapy for SMA

Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First
CompanyDrug

Novo’s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First

Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low
CompanyDrug

Novo Nordisk’s Semaglutite Alzheimer’s Failure Sends Stock to 4-Year Low

Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific
CompanyDrug

Zelgen’s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific